When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRVB - Provention Bio commences late-stage study of T1D candidate teplizumab
Provention Bio Inc.
Dosing is underway in a Phase 3 clinical trial, PROTECT, evaluating Provention Bio's (NASDAQ:PRVB) PRV-031 (teplizumab) in patients with recent-onset type 1 diabetes (T1D).
More news on: Provention Bio, Inc., Healthcare stocks news,